Doximity (DOCS) – Research Analysts’ Weekly Ratings Changes

A number of firms have modified their ratings and price targets on shares of Doximity (NASDAQ: DOCS) recently:

• 2/11/2026 – Doximity had its price target lowered by analysts at Barclays PLC from $63.00 to $38.00. They now have an “overweight” rating on the stock.
• 2/10/2026 – Doximity had its price target lowered by analysts at Mizuho from $45.00 to $34.00. They now have a “neutral” rating on the stock.
• 2/9/2026 – Doximity was given a new $34.00 price target on by analysts at Canaccord Genuity Group Inc.. They now have a “buy” rating on the stock.
• 2/6/2026 – Doximity was given a new $38.00 price target on by analysts at KeyCorp.
• 2/6/2026 – Doximity had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $46.00 to $34.00. They now have a “neutral” rating on the stock.
• 2/6/2026 – Doximity was given a new $25.00 price target on by analysts at BMO Capital Markets.
• 2/6/2026 – Doximity had its price target lowered by analysts at Piper Sandler from $70.00 to $40.00. They now have an “overweight” rating on the stock.
• 2/6/2026 – Doximity had its price target lowered by analysts at Wells Fargo & Company from $55.00 to $45.00. They now have an “overweight” rating on the stock.
• 2/6/2026 – Doximity had its price target lowered by analysts at Morgan Stanley from $65.00 to $49.00. They now have an “overweight” rating on the stock.
• 2/6/2026 – Doximity was upgraded by analysts at JPMorgan Chase & Co. from an “underweight” rating to a “neutral” rating. They now have a $40.00 price target on the stock, down previously from $62.00.
• 2/6/2026 – Doximity had its price target lowered by analysts at BTIG Research from $80.00 to $50.00. They now have a “buy” rating on the stock.
• 2/6/2026 – Doximity had its price target lowered by analysts at Needham & Company LLC from $75.00 to $55.00. They now have a “buy” rating on the stock.
• 2/6/2026 – Doximity had its price target lowered by analysts at Truist Financial Corporation from $62.00 to $37.00. They now have a “buy” rating on the stock.
• 2/4/2026 – Doximity was given a new $45.00 price target on by analysts at Mizuho.
• 1/20/2026 – Doximity was upgraded by analysts at Wells Fargo & Company from an “equal weight” rating to an “overweight” rating. They now have a $55.00 price target on the stock, down previously from $65.00.
• 1/9/2026 – Doximity was upgraded by analysts at The Goldman Sachs Group, Inc. from a “neutral” rating to a “buy” rating. They now have a $49.00 price target on the stock.
• 1/8/2026 – Doximity is now covered by analysts at Royal Bank Of Canada. They set an “outperform” rating and a $59.00 price target on the stock.
• 1/8/2026 – Doximity was given a new $62.00 price target on by analysts at Truist Financial Corporation.
• 1/8/2026 – Doximity had its price target lowered by analysts at KeyCorp from $75.00 to $60.00. They now have an “overweight” rating on the stock.
• 1/8/2026 – Doximity was given a new $48.00 price target on by analysts at Canaccord Genuity Group Inc..
• 1/8/2026 – Doximity had its “outperform” rating reaffirmed by analysts at Evercore Inc.
• 1/8/2026 – Doximity was upgraded by analysts at Truist Financial Corporation from a “hold” rating to a “buy” rating.
• 12/29/2025 – Doximity had its “strong-buy” rating reaffirmed by analysts at Raymond James Financial, Inc..

Doximity, Inc, headquartered in San Francisco, California, operates the leading professional medical network for healthcare professionals in the United States. Founded in 2011 by Jeff Tangney and Shari Buck, the company set out to create a secure digital environment where physicians, nurse practitioners and physician assistants can collaborate, share information and stay current with clinical news. Doximity went public in June 2021 and trades on the NASDAQ under the ticker symbol “DOCS.”

The core offering of Doximity is its HIPAA-compliant communication platform, which includes a secure messaging system, digital fax services and telehealth capabilities.